Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

3.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.2K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Fattening mother's milk with oxytocin.

Science signaling·2026
Same author

In Science Journals.

Science (New York, N.Y.)·2026
Same author

In Science Journals.

Science (New York, N.Y.)·2026
Same author

In Science Journals.

Science (New York, N.Y.)·2026
Same author

RXRα marks the spot for Crohn's disease.

Science signaling·2026
Same author

In Science Journals.

Science (New York, N.Y.)·2026
Same journal

ZNRF3 and RNF43 are active monomeric E3 ubiquitin ligases that self-associate.

Science signaling·2026
Same journal

Allosteric ligands with distinct properties uncover tissue-specific physiological regulation mediated by free fatty acid receptor 2.

Science signaling·2026
Same journal

Diacylglycerol kinase ζ in B lymphocytes supports CD40-mediated immune synapse formation, mTORC1 signaling, and plasma cell fate.

Science signaling·2026
Same journal

The APC/C adaptor Cdh1 stabilizes STING to potentiate innate immune activation in renal cell carcinoma.

Science signaling·2026
Same journal

Virion display reveals MD-1 as an endogenous agonist for the orphan receptor GPRC5B.

Science signaling·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2025

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

1.8K

Protecting the liver with PKD1.

Wei Wong1

  • 1Science Signaling, AAAS, Washington, DC 20005, USA.

Science Signaling
|August 27, 2024
PubMed
Summary
This summary is machine-generated.

Somatic cells lacking the PKD1 gene can prevent fatty liver disease. This genetic modification stops liver fat accumulation without causing tumor formation.

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.4K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.5K

Related Experiment Videos

Last Updated: Jun 15, 2025

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

1.8K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.4K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.5K

Area of Science:

  • Hepatology and molecular biology
  • Genetics and disease mechanisms

Background:

  • Fatty liver disease is a growing health concern with limited treatment options.
  • The role of Polycystic Kidney Disease 1 (PKD1) in liver physiology is not fully understood.

Purpose of the Study:

  • To investigate whether somatic cells deficient in PKD1 can prevent fatty liver disease.
  • To determine if PKD1 deficiency in somatic clones leads to tumor development.

Main Methods:

  • Utilizing genetic models to create somatic clones with targeted PKD1 deficiency.
  • Assessing liver health and fat accumulation in the presence of PKD1-deficient clones.
  • Monitoring for any signs of tumorigenesis in the liver.

Main Results:

  • Proliferation of somatic clones lacking PKD1 effectively prevented the development of fatty liver disease.
  • No evidence of tumor formation was observed in the livers of these models.

Conclusions:

  • Targeting somatic cells for PKD1 deficiency presents a potential therapeutic strategy for fatty liver disease.
  • PKD1 deficiency in somatic clones appears to be a safe approach, not inducing cancer.